• Tiziana Life Sciences completed patient enrollment in a randomized, double-blind, placebo-controlled Phase 2a trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.
• Topline results are expected in late Q3 2026, with data slated for presentation at the ACTRIMS-ECTRIMS meeting in October 2026.
• The study is designed to assess whether the therapy can reduce neuroinflammation and translate into clinical benefit, addressing a segment with limited treatment options.
• The trial enrolled 48 patients across U.S. sites, testing two dose levels versus placebo over 12 weeks, followed by an open-label extension intended to support longer-term safety and durability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211100OMX_____CNEWS_EN_GNW9724702_en) on May 21, 2026, and is solely responsible for the information contained therein.